论文部分内容阅读
据出席２００１年８月“福建国际医药生物技术研讨会“的部分专家介绍，眼下国内医药生物技术研究机构状况令人担忧，人才流失，科研队伍青黄不接，以往的研究项目已经落后于形势，新一代的研究又缺乏资金和人才。同时，中国新药生产厂家中，合资厂、技术合作厂占主导地位，缺
According to some experts who attended the “Fujian International Pharmaceutical Biotechnology Symposium” in August 2001, the current situation of domestic pharmaceutical biotechnology research institutions is worrisome, the brain drain, and the research team is not connected. Previous research projects have lagged behind the situation. The study also lacked funds and talent. At the same time, joint ventures and technical cooperation plants dominate the Chinese new drug manufacturers.